PL1734987T3 - Interferon beta w terapii antywirusowej w przypadku chorób układu oddechowego - Google Patents

Interferon beta w terapii antywirusowej w przypadku chorób układu oddechowego

Info

Publication number
PL1734987T3
PL1734987T3 PL05708482T PL05708482T PL1734987T3 PL 1734987 T3 PL1734987 T3 PL 1734987T3 PL 05708482 T PL05708482 T PL 05708482T PL 05708482 T PL05708482 T PL 05708482T PL 1734987 T3 PL1734987 T3 PL 1734987T3
Authority
PL
Poland
Prior art keywords
agent
interferon
beta
respiratory diseases
virus therapy
Prior art date
Application number
PL05708482T
Other languages
English (en)
Polish (pl)
Inventor
Donna Elizabeth Davies
Peter Alexander Blanch Wark
Stephen Holgate
Sebastian L Johnston
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southampton filed Critical Univ Southampton
Publication of PL1734987T3 publication Critical patent/PL1734987T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL05708482T 2004-03-12 2005-03-07 Interferon beta w terapii antywirusowej w przypadku chorób układu oddechowego PL1734987T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
EP05708482A EP1734987B1 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (1)

Publication Number Publication Date
PL1734987T3 true PL1734987T3 (pl) 2010-10-29

Family

ID=32117582

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05708482T PL1734987T3 (pl) 2004-03-12 2005-03-07 Interferon beta w terapii antywirusowej w przypadku chorób układu oddechowego

Country Status (12)

Country Link
US (3) US7569216B2 (cg-RX-API-DMAC7.html)
EP (2) EP1734987B1 (cg-RX-API-DMAC7.html)
JP (2) JP4807526B2 (cg-RX-API-DMAC7.html)
AT (1) ATE466591T1 (cg-RX-API-DMAC7.html)
CA (2) CA2787978A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005021078D1 (cg-RX-API-DMAC7.html)
DK (1) DK1734987T3 (cg-RX-API-DMAC7.html)
ES (1) ES2343732T3 (cg-RX-API-DMAC7.html)
GB (1) GB0405634D0 (cg-RX-API-DMAC7.html)
PL (1) PL1734987T3 (cg-RX-API-DMAC7.html)
PT (1) PT1734987E (cg-RX-API-DMAC7.html)
WO (1) WO2005087253A2 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
EP1922081B1 (en) * 2005-09-09 2012-08-15 Imperial Innovations Limited Interferon lambda therapy for treatment of respiratory diseases
AU2005336519B2 (en) * 2005-09-20 2012-05-10 New York University Method of treating pulmonary disease with interferons
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
BRPI0819932A2 (pt) * 2007-12-13 2019-07-30 Glaxo Group Ltd composição, uso de uma composição, dispositivo nebulizador, inalador ou intranasal, processos para produzir uma composição farmacêutica e uma composição polipeptídica, e, uso de um tampão fisiologicamente aceitável.
AU2009344851A1 (en) * 2008-12-19 2011-06-23 The Regents Of The University Of California Use of epidermal growth factor inhibitors in the treatment of viral infection
EP2506759A4 (en) 2009-12-02 2015-05-20 Neetour Medical Ltd SURVEILLANCE BASED ON HEMODYNAMIA AND ASSESSMENT OF RESPIRATORY DISEASES
DK2544705T3 (en) * 2010-03-12 2016-09-19 Synairgen Res Ltd INTERFERON BETA TO USE IN THE LOWER AIR TRANSMISSION CAUSED BY INFLUENZA
PL3669892T3 (pl) 2010-09-22 2024-10-07 Ena Respiratory Pty Ltd Kompozycja do zastosowania w metodzie immunostymulacyjnej
JP6730926B2 (ja) 2014-01-08 2020-07-29 プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド 融合ポリペプチドおよび使用方法
JP7317796B2 (ja) * 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
FI3728289T3 (fi) 2017-12-21 2025-11-11 Axelia Oncology Pty Ltd Optimoidut yhdisteet
WO2020168033A2 (en) * 2019-02-13 2020-08-20 University Of Florida Research Foundation, Inc. Targeting lung-resident tnfr2+ cdc2 (r2d2) subpopulation to treat asthma
KR20220050873A (ko) 2019-06-26 2022-04-25 악셀리아 온콜로지 피티와이 리미티드 신규한 분자
US20230338475A1 (en) 2020-07-20 2023-10-26 Synairgen Research Limited USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
DK4240396T5 (da) * 2020-11-04 2025-04-07 Ethris Gmbh Ifn-lambda-mrna til behandling af virusinfektioner
US20250281576A1 (en) * 2021-01-13 2025-09-11 Abion Inc. Prophylactic administration method against respiratory virus, comprising administering interferon-beta to potential respiratory virus-infected subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
ES2245780T3 (es) * 1994-05-18 2006-01-16 Nektar Therapeutics Metodos y composiciones para la formulacion de interferones como un polvo seco.
US6030609A (en) * 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
EP1334128A2 (en) 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
WO2002072019A2 (en) * 2001-03-13 2002-09-19 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
AU2003215136A1 (en) 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
WO2004037995A2 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
US7157559B2 (en) 2003-08-07 2007-01-02 Zymogenetics, Inc. Homogeneous preparations of IL-28 and IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
WO2005097165A2 (en) 2004-04-02 2005-10-20 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection

Also Published As

Publication number Publication date
US9089535B2 (en) 2015-07-28
HK1097181A1 (en) 2007-06-22
CA2558212C (en) 2012-11-27
GB0405634D0 (en) 2004-04-21
JP4807526B2 (ja) 2011-11-02
JP2007528890A (ja) 2007-10-18
DE602005021078D1 (de) 2010-06-17
DK1734987T3 (da) 2010-08-30
CA2787978A1 (en) 2005-09-22
US8273342B2 (en) 2012-09-25
US20090257980A1 (en) 2009-10-15
WO2005087253A3 (en) 2005-11-24
EP2206512A3 (en) 2013-01-09
JP2011144201A (ja) 2011-07-28
PT1734987E (pt) 2010-07-06
EP2206512A2 (en) 2010-07-14
WO2005087253A2 (en) 2005-09-22
EP1734987A2 (en) 2006-12-27
ES2343732T3 (es) 2010-08-09
EP1734987B1 (en) 2010-05-05
CA2558212A1 (en) 2005-09-22
US20130209399A1 (en) 2013-08-15
US20070134763A1 (en) 2007-06-14
US7569216B2 (en) 2009-08-04
ATE466591T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
PL1734987T3 (pl) Interferon beta w terapii antywirusowej w przypadku chorób układu oddechowego
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
AP1712A (en) Novel tiotropium-containing inhalation powder
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
GB0127989D0 (en) Medicament dispensing system
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
MY155912A (en) New inhalable powder containing tiotropium
ATE495744T1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
JP2011144201A5 (cg-RX-API-DMAC7.html)
DE602006004963D1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
MX2007012700A (es) Compuestos organicos.
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
SG149876A1 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
EP2380569A3 (de) Osmolyte zur Behandlung von allergisch oder viral bedingten Atemwegserkrankungen
NZ547276A (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
DE602006012332D1 (de) Kombination von verbindungen, die bei der behandlung von atemwegserkrankungen verwendet werden können, insbesondere bei chronisch obstruktiver lungenerkrankung (copd) und asthma
EA200701077A1 (ru) Применение конъюгатов липидов при лечении заболеваний
WO2011110861A3 (en) Therapy for influenza like illness
MXPA04007294A (es) Composicion para inhalacion.
MXPA04002401A (es) Nuevos medicamentos para inhalacion.
Miller Combined inhaled bronchodilators in COPD
IL165574A0 (en) Compositions for the transport of therapeutic molecules into the lungs and use thereof for the treatment of lung cancers and pulmonary diseases